Showing items 1 - 3 of 3

Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites

- Liu, Zheng, Martin, Jennifer H., Hatzimihalis, Athena, Campbell, Ian, Crowley, Simone, Beale, Phillip J., Karapetis, Christos S., Price, Timothy, Burge, Mathew E., Michael, Michael, Liauw, Winston, Mclachlan, Sue-Anne, Link, Emma, Matera, Anetta, Thompson, Michael, Jefford, Michael, Hicks, Rod J., Cullinane, Carleen

Immunomodulatory activities of pixatimod: Emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors

- Hammond, Edward, Haynes, Nicole M., Cullinane, Carleen, Brennan, Todd V., Bampton, Darryn, Handley, Paul, Karoli, Tomislav, Lanksheer, Fleur, Lin, Liwen, Yang, Yiping, Dredge, Keith

An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development

- Cullinane, Carleen, Dorow, Donna S., Kansara, Maya, Conus, Nelly, Binns, David, Hicks, Rodney J., Ashman, Leonie Kay, McArthur, Grant A., Thomas, David M.

  • 1
  • Disclaimer
  • Privacy
  • Copyright
  • Contact
  • Deposit